Snehal Patel Buys 2,500 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 2,500 shares of the company’s stock in a transaction that occurred on Friday, March 22nd. The shares were bought at an average price of $19.98 per share, for a total transaction of $49,950.00. Following the transaction, the chief executive officer now directly owns 5,347,777 shares in the company, valued at $106,848,584.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Snehal Patel also recently made the following trade(s):

• On Wednesday, March 20th, Snehal Patel bought 1,500 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $17.68 per share, for a total transaction of $26,520.00.
• On Monday, March 4th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $13.03 per share, for a total transaction of $53,423.00.
• On Thursday, February 15th, Snehal Patel acquired 12,700 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $11.07 per share, for a total transaction of $140,589.00.

Greenwich LifeSciences Stock Performance

GLSI opened at $20.00 on Thursday. The company’s fifty day moving average price is $12.71 and its two-hundred day moving average price is $10.85. Greenwich LifeSciences, Inc. has a 1-year low of $7.58 and a 1-year high of $21.44.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of Greenwich LifeSciences in a report on Wednesday, February 28th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Walleye Capital LLC acquired a new position in Greenwich LifeSciences during the second quarter worth $90,000. Goldman Sachs Group Inc. purchased a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $104,000. Bank of America Corp DE raised its holdings in shares of Greenwich LifeSciences by 100.2% in the first quarter. Bank of America Corp DE now owns 6,213 shares of the company’s stock valued at $122,000 after purchasing an additional 3,110 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $130,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Greenwich LifeSciences in the second quarter valued at about $150,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.